Dr. Reckamp on Targeted Therapy Options for Rare Mutations in NSCLC
Karen L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.
Best Initial Treatment Strategies for EGFR-Mutant Lung Cancer
This review will focus on current therapies used in the first-line setting for advanced EGFR mutation positive non–small cell lung cancer (NSCLC) followed by emerging data that may lead to a transition in the choice for initial therapy in these patients.
2 Clarke Drive Cranbury, NJ 08512